The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aims: Patients with type 2 diabetes and insulin resistance may require high insulin doses to control hyperglycaemia. The addition of glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) to basal insulin therapy has been shown to reduce insulin requirement while reducing insulin‐associated weight gain [1,2]. The effect of GLP ‐1 RA therapy added to intensive (basal/bolus) insulin therapy has not been studied in a prospective trial. This trial evaluated the effect of the addition of liraglutide to high‐dose intensive insulin therapy compared with standard insulin up‐titration in obese insulin‐resistant patients with type 2 diabetes requiring high‐dose insulin therapy. Methods: Thirty‐seven subjects with type 2 diabetes requiring >100 units of insulin daily administered either by continuous subcutaneous insulin infusion ( CSII ) or by multiple daily injections ( MDIs ) with or without metformin were randomized to receive either liraglutide plus insulin (LIRA) or intensive insulin only (controls). Liraglutide was initiated at 0.6 mg subcutaneously (sq) per day and increased to either 1.2 or 1.8 mg daily in combination with intensive insulin therapy. Controls received intensive insulin up‐titration only. Results: At 6 months, subjects receiving liraglutide plus insulin experienced statistically significant reductions in HbA1c , weight, insulin dose and glycaemic variability (GV) by continuous glucose monitor ( CGM ) compared with the control group receiving insulin only. Conclusions: Adding liraglutide to intensive high‐dose (basal/bolus) insulin therapy results in greater improvement in glycaemic control than insulin therapy alone, with additional benefits of weight loss and reduced GV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
“Indeed, there is increasing evidence for and interest in this approach (50).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
“0001]; no significant change with standard insulin therapy alone).(54) An uncontrolled study of 20 Japanese patients with T2D also found liraglutide to significantly reduce MAGE (from 94 to 44 mg/dL; P < 0.”
Background
Metadata
- Authors
- Lane, W., Weinrib, S., Rappaport, J., & Hale, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-03-25
- Volume
- 16
- Issue
- 9
- Pages
- 827-832
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2157354650
- Cited by
- 91
- References
- 2
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial. https://app.cochat.ai/papers/10.1111/dom.12286
- The paper
- Lane, W., Weinrib, S., Rappaport, J., & Hale, C. (2014). The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12286
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.